6 GHz unlicensed access and Wi-Fi 6E to add billions to Indonesian and African economies, reveals Dynamic Spectrum Alliance
It is predicted that unlicensed access to the 6 GHz band will add US$ 187.63…
It is predicted that unlicensed access to the 6 GHz band will add US$ 187.63…
Munich, 24 February 2022 – Codasip, the leader in processor design automation, today announced the…
Ativa suite provides 360° intelligence and operations across digital experiences, apps, services, networks and infrastructure…
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on…
WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical…
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel…
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor,…
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults…
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM,…
— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96…
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader…
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits…
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with…
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022,…
Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling…
WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (“Eagle” or the…
– Topline Analysis from Phase 3 DeFi Trial Expected to be Triggered in the First Quarter…